Orchard Australia

Orchard Therapeutics is a global biotechnology company specializing in the development of hematopoietic stem cell (HSC) gene therapies for rare and life-threatening diseases. The company's approach involves genetically modifying a patient's own stem cells using lentiviral vectors to provide a potential one-time curative treatment. Its lead product, Libmeldy (atidarsagene autotemcel), is the first therapy approved for the treatment of early-onset metachromatic leukodystrophy (MLD) in Europe, the UK, and the US (where it is marketed as Lenmeldy). Orchard's pipeline includes advanced programs for Wiskott-Aldrich syndrome and various mucopolysaccharidosis disorders. In early 2024, the company was acquired by Kyowa Kirin to serve as a cornerstone of its global genetic medicine strategy.